NCT06658522View on ClinicalTrials.gov

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions

Pulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension WHO Group IPulmonary Arterial Hypertension

Interventions

DRUG

Sotatercept

Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks

Trial Locations (1)

1081HV

RECRUITING

Amsterdam UMC, location VUMC, Amsterdam

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Amsterdam UMC, location VUmc

OTHER